

## C. Brendan Montano MD

### Education:

1964-1968	College of the Holy Cross	Worcester, MA
1968-1972	Albany Medical College	Albany, NY
1972-1975	St. Francis Hospital and Medical Center	Hartford, CT
	Internal Medicine Residency, Chief Resident (1975)	
	Yale University-Resident Rotations in Neurology, Gastroenterology and Dermatology	

### Affiliations:

2002-Present	Connecticut Clinical Research, Director, Principle Investigator
1978-Present	Internal Medicine, Private Practice, Special interest in Preventive Medicine and Mood Disorders, Cromwell, CT
1976-Present	Attending Physician at Middlesex Memorial Hospital, Department of Medicine
2006-2009	Journal of Clinical Psychiatry for Primary Care: Editorial Board
1978-2009	Assistant Clinical Instructor, University of Connecticut School Of Medicine, Department of Family Practice
2006-2010	CME Institute: Board of Directors
1972-2010	Courtesy Privileges St. Francis Hospital, Department of Medicine, Hartford, CT
1991-2004	Director, New Beginnings Weight Management Center, Cromwell, CT
1983-1993	Medical Director at Roncalli Institute, Cromwell Crest Convalescent Facility—Cromwell, CT
1985-1991	New England Heart Center—Medical Director-Manchester, CT

### National Advisory Board and/or CME Consultant/Presenter:

Astra Zeneca, Bayer, GSK, Eli-Lilly, Forest, Lundbeck, Merck, Neos, Ortho-McNeil, Organon, Otsuka, Pfizer, Rhodes, Roche, Shire, Sunovion, Takeda, Wyeth

### Research: Clinical Trial Experience

2015	Alcobra AL016: The Measure Study-A Phase 3 Study of MDX 1400mg Daily Compared with Placebo in Adults with ADHD
2014	Daiichi Sankyo Inc. DS5565-A-E309: Treatment of Pain Associated With Fibromyalgia
	Daiichi Sankyo Inc. DS5565-A-E312: An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
	Forest Laboratories LVM-MD-15: A Multicenter, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder
	Sunovion SEP360-301: Dasotraline Adult ADHD Study
2013	Brigham and Women's Hospital CIRT: Cardiovascular Inflammation Reduction Trial
2012	Forest Research Institute VLZ-MD-01: A Double-Blind, Placebo- And Active- Controlled, Fixed-Dose Study Of Vilazodone In Patients With Major Depressive Disorder.
	Bristol-Myers Squibb CN162-010/079: A Multicenter, Randomized, Double-Blind, Active-Controller, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression-Extension Study
2011	Eli Lilly 14099: A Study of Duloxetine in Adolescents with Juvenile Primary Fibromyalgia Syndrome
	Bristol-Myers Squibb CN162-007/0026: A Multicenter, Randomized, Double-Blind, Active-Controller, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression.
	Forest Research Institute NAC-MD-02 A Multicenter, Single-Arm, Free Tablet Combination, Long-Term Study To Evaluate The Safety Of Nebivolol In Combination with Valsartan In Patients With Stage 1 or Stage 2 Essential Hypertension.
2010	Forest Research Institute LVM-MD-10: A Double-Blind, Placebo-Controlled, Fixed- Dose Study of Levomilnacipran SR in Patients with Major Depressive Disorder.
	Eli Lilly F1J-US-HMGU: Duloxetine Versus Placebo In The Acute Treatment of Patients With Major Depressive Disorder And Associated Painful Physical Symptoms.
	Pfizer 3151A1-4415-NA: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinate Sustained Release.

- Forest Research Institute MLN-MD-28: A Multicenter, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy Of Milnacipran in Patients with an Inadequate Response to Duloxetine For The Treatment of Fibromyalgia.
- Pfizer 3151A1-4337-WW (B2061010) A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With Major Depressive Disorder (MDD) Treated For 24 Weeks With Open-Label 50 Mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)
- Otsuka 31-08-255 A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
- Shire SPD489-205 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults with Clinically Significant, Persistent Executive Function Impairments (EFE) and Partial or Full Remission of Recurrent Major Depressive Disorder
- Forest LVM MD 04 A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder
- Forest LVM MD 01 A Double Blind Placebo Controlled Fixed-Dose Study of F2695 SR in Patients With Major Depressive Disorder
- Pfizer/Wyeth 3151 A1 4437 A Randomized, Double-Blind, Parallel Group Study to Compare Discontinuation Symptoms in Abrupt Discontinuation Versus a 1-week Tapering Regimen in Subjects with Major Depressive Disorder (MDD) Treated for 24 Weeks with Open-Label 50 mg Desvenlafazine Succinate Sustained-Release Formulation (DVS SR)
- Pfizer/Wyeth 3151 A1 3364 A Multicenter, Parallel-Group, Randomized, 10 Week, Double-Blind, Placebo-Controlled Parallel Group Study to Compare Discontinuation Symptoms in Abrupt Discontinuation Versus a 1-week Tapering Regimen in Subjects with Major Depressive Disorder (MDD) Treated for 24 Weeks with Open-Label 50 mg Desvenlafazine Succinate Sustained-Release Formulation (DVS SR)
- Eli Lilly F1J MC HMGU Duloxetine Versus Placebo in the Acute Treatment of Patients with Major Depressive Disorder and Associated Painful Physical Symptoms
- 2009 Eli Lilly F1J-MC-HMGG: a Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients with Fibromyalgia
- Eli Lilly H6P-MC-HDAY A Study to Assess the Long-Term Efficacy and Safety of Olanzapone and Fluoxetine Combination Versus Fluoxetine Treatment-Resistant Depression Signatures
- Eli Lilly F1J-US-HMGL A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment
- Wyeth 3151A1 -3362 A Multicenter Randomized, Double-Blind Placebo- Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (10 and 50mg/day) of DVS SR Tablets in Adult Outpatients with Major Depressive Disorder.
- Pfizer 3151A1-3364 (B2061029): A Multicenter, Parallel-Group Randomized, 10 Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 Mg Of Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR) In The Treatment Of Per- And Postmenopausal Women With Major Depressive Disorder.
- Forest Research Institute LVM-MD-04: A Long-Term, Open-Label Extension Study of F2695 SR in Adult Patients with Major Depressive Disorder
- Forest Research Institute LVM-MD-01: A Double-Blind, Placebo-Controller, Fixed-Dose study of F2695 SR in Patients with Major Depressive Disorder
- Forest MLN MD 28 A Multicenter, Randomized , Double-Blind, Placebo-Controlled switch study To Evaluate The Safety, Tolerability and Efficacy Of Milnacipran In Patients With An Inadequate Response To Duloxetine For the Treatment of Fibromyalgia
- An Open-Label Study To Evaluate The Prevalence Of Phenotypic Poor Metabolizers At CYP2D6 Among Venlafaxine-Treated Out Patients With Depression.
- Forest MLN MD 27 A Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran When Added to Pregabalin in the Treatment of Fibromyalgia
- 2008 Takeda A Randomized, double-Blind, Parallel-Group, Placebo-Controlled, Fixed -Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder.
- Novartis Protocol CSPP100A US07 An 8-week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese patients (BMI >= 30 ) with Stage 2 Hypertension.
- Eli Lilly Protocol F1J-MC-HMGC Effects of Duloxetine 60mg Once Daily Versus Placebo in Patients with Chronic Low back Pain
- Eli Lilly Protocol F1J-MC-HMGB Flexible Dosed Duloxetine Versus/Placebo in the Treatment of Fibromyalgia
- Eli Lilly Protocol F1J-MC-HMEZ An open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients with Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain.
- 2007 Schwarz Biosciences Protocol SP888 A Parallel, Randomized, Double-blind, Placebo-Controlled, Multicenter Proof of Concept

- Trial to Assess the Efficacy and Safety of two Different Transdermal Doses of Rotigotine in Subjects with Signs and Symptoms Associated with Fibromyalgia Syndrome.
- Forest/Cypress Protocol MLN-MD-06 A Phase III, Multicenter. Open-Label, Flexible-Dosing Study of Milnacipran For The Treatment Of Fibromyalgia.
- Forest/Cypress Protocol MLN-MD-03 “A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study Of Milnacipran For the Treatment of Fibromyalgia.”
- Eli Lilly F1J-MC-HMEO Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain
- Wyeth 3151A1-402WW A Multicenter, Randomized, 8 Week Double Blind Acute Phase Followed by a 6 Month Continuation Phase (Open Label or Double blind) study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women with Major Depressive Disorder.
- Novartis CAGO178A2301E1 An 8 Week, Randomized, Double-Blind, Fixed- Dosage, Placebo-Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52 Week Open Label Extension.
- Sanofi Aventis EFC 5582 An Eight-week, Multcenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating the Efficacy, Safety and Tolerability of Two Fixed Doses (100mg and 30 Mg Once Daily) of Saredutant in Patients with Generalized Anxiety Disorder.
- 2006 Takeda Protocol# 01-05-TL-322OPI-001 “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 and Pioglitazone HCl in Subjects with Type 2 Diabetes.”
- Eli Lilly Protocol # F3Z-US-IOOV(a) “ The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control.”
- Sanofi Aventis Protocol EFC5116 “An eight –week, double-blind, placebo controlled, multicenter study with Escitalopram as a positive control, evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A in outpatients with MDD”
- Wyeth Protocol 3151A4-327-330 A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy and Tolerability Study of 4Fixed Oral Doses of DVS SR in Adult Outpatients with Fibromyalgia Syndrome.
- Wyeth Protocol 00600B1-416-US Patient Outcomes with Educaiton, Drug Therapy and Support(POETS) A Multiconeter, Open-Label, Randomized Study to Evalute Depressed Subjects treated with Venlafaxine Extended Release vs Venlafaxine Extended Release Plus the Dialogues to Talk Program in a Primary Care Setting
- Eli Lilly Protocol F1J-US-HMGB Flexible Dosed Duloxetine Versus \ Placebo in the Treatment of Fibromyalgia
- AstraZeneca Protocol D1448C00005 “ A Multi-Centre, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Monotherapy in the Maintenance treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period (Amethyst Study)
- Aventis Protocol HMR3647A/4019 “ A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of Telithromycin verses Azithromycin in Outpatients with Community-Aquired Lower Respiratory Tract Infections”
- 2005 Predix Pharmaceuticals Protocol PRX-CP-007 “A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, and Tolerability Of PRX-0023 In Patients With Generalized Anxiety Disorder (GAD)
- Eli-Lilly Protocol F1J-MC-HMEF(a) “Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome”
- 2004 F. Hoffmann-La Roche LTD Protocol ML 18056 “Prospective, Open-label, Multi-center, Two-part Study To Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy In Women With Postmenopausal Osteoporosis Or Osteopenia Transitioned from Once-Weekly Alendronate Or Risedronate2
- F. Hoffmann-La Roche LTD Protocol MA17843 “Randomized, Open-Label, Multi-Center Study to Investigate Patient Preference on Dosing in Women with Postmenopausal Osteoporosis Treated with Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six-Month, Two-Period Crossover Study”
- 2003 GSK Protocol AK103091: A Multicenter, Double-Blind Placebo Controlled Comparison of the Efficacy and Safety of Flexible Dose Extended-Release Bupropion Hydrochloride (HCl) 300-450 mg/day and Placebo Administred for Eight Weeks for the Treatment of Adult Outpatients with Major Depressive Disorder Including Symptoms of Decreased Energy, Pleasure and Interest.
- 2003 Eli-Lilly Protocol F1J-MC-HMBV: Duloxetine Versus Placebo in the Treatment of Elderly Patients with Major Depressive Disorder.
- Eli-Lilly Protocol H6K-MC-LVFN: An Open-Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered “On Demand” to Men of Various Populations with Erectile Dysfunction.
- 2002 Eli-Lilly Protocol F1J-US-HMBZ: Open –Label Treatment with Duloxetine Hydrochloride once-Daily dosing for Evaluation of Stabilization Dose in Patients with Major Depression.
- 2001 Takeda Protocol 01-00-TL-OPI-506: A Randomized Comparator, Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl Versus Glyburide with Metformin and Insulin as Part of Step Therapy in Subjects with Type 2 Diabetes.

- Aventis Pharmaceuticals Inc.: Ketek Protocol HMR3647A/3014 Telithromycin Randomized, Open-Label, Multicenter Trial of the Safety and Effectiveness of Oral Telithromycin and Amoxicillin/Clavulanic Acid in Outpatients with Respiratory Tract Infections in Usual Care Settings
- 2000 GSK Protocol AK140020 Study Chairperson, Protocol Sexual Dysfunction with Antidepressant Medication in the Primary Care Setting
- Bristol-Meyers Squibb Protocol A1420088 Bronchitis and Pneumonia
- 1998 Hoffman-Roche Protocol M37048/NR158 Krista Treatment Plus Diet in Obese Type 2 Diabetes Patients on Metformin
- Hoffman-Roche Protocol M37049/NR158 Orlistat Plus Diet in Obese Hypertensive Patients
- 1996 Searle Protocol 1296011 Convince: Hypertension
- Forrest Protocol CITMD49815 Early Experience: Depression
- Target: Hyperlipidemia—Park-Davis Phase V
- 1994 Pratt Protocol P-0001 GEST: Diabetes
- Pfizer Protocol R-0235 Sertraline: Depression, open label, multicenter
- SKB Protocol PAR/23 Paroxetine: Depression Phase III

### **National Programs:** *(a partial list of programs delivered)*

- 2017 University at Sea – Weeklong CME Program Presenter – “Psychiatry Update in Primary Care”
- 2016 Adzenys Forum
- Shire – Sponsored Product Theater at Primed
- Albany Medical College – Sinatra Series
- Takeda Multiple MDD Program Presenter
- National Association for Continuing Medical Education (NACME) – CME Programs (Bipolar, ADHD, Depression)
- Otsuka/Lundbeck – National Speaker for APNA in Hartford, CT – Partially Responsive Depression
- 2015 Shire – “B.E.D. in Adults” Speaker
- Merck – Speaker for Insomnia Series – Belsomra
- National Association for Continuing Medical Education (NACME) – CME Programs (Bipolar, ADHD, Depression)
- 2014 Takeda EOD (Expert on Demand)
- Otsuka/Lundbeck – National Speaker Rexulti Product Theater
- 2013 Takeda Brintellix/Trintellix Speaker
- Takeda Depression Network Speakers Bureau
- 2012 Shire ADHD – “Beyond Childhood, Recognizing ADHD in Adults” for APNA
- 2010 Eli Lilly – “Pathophysiology of Pain”
- Shire – ADHD Roundtable
- 2009 CME series: Adult ADHD Initiative (Dr. Leonard Adler-chairman)
- Presented Bipolar Depression Training with Dr. Michael Thase – AZ
- 2007 Depression, Bipolar Depression, ADHD
- 2006 Sleep Consultant Network: From the New Understandings of Sleep Science to Novel Therapeutic Targets for Insomnia.
- CME National Series: Recognition and Treatment of Somatic Symptoms of Depression. Co-Author and CO-Chair with Rakish Jain MD
- CME National Series: Generalized Anxiety Disorder in Primary Care Setting; Author and Program Chair
- CME National Series New aspects of Depression in Primary Care; Author and Program Chair
- 2005 XIII International Congress on Anti-Aging Medicine: Medical Spas: A New Emerging Field: Stress Management
- CME Symposia Series: “Improving Physical and Mental Outcomes: How Anxiety Impacts Comorbid Conditions – A Primary Care Physician’s Perspective.” Author and Chair
- ADHD in Adults and Children
- Faces of Depression: MDD
- CME Symposia Series: “Using a Collaborative Care Approach to Achieve Successful Treatment Outcomes in the Management of Bipolar Disorder”
- AAPA 33<sup>rd</sup> Annual Physician Assistant Conference: Faculty; “Effective Management Strategies for Depression”
- CME Symposia Series: “Identification and Management of Bipolar Disorder in the Primary Care Setting”
- “New Approaches in the Management of Post Menopausal Osteoporosis”
- 2004 “Depression and Anxiety in Primary Care” CME symposia, Primary Psychiatry
- 2003 “Two Primary Care Challenges: Caring for the Patient with Headache and Depression”
- “Dual Diagnosis and Family Dynamics in Recovery” conference chair, 8 CME credits, Monroe, LA
- “A New Frontier in Internal Medicine: Complete Symptom Resolution in Depression” San Diego, CA
- “Clinical Perspectives on a New Treatment Option for Attention Deficit Hyperactivity Disorder”

- 2002 Delivered symposia nationwide: "Implications for the Primary Care Physician: Treating the Symptoms of Bipolar mania and Schizophrenia
- 2002 CME Series: "Understanding Depression: Matching the Neurotransmitter to the Patient"
- 2000 CME Series: Managing Depressive Sub-Types: Atypical Depression in the Primary Care Practice, co-chair James Pradko, MD
- 1999 Delivered symposia nationwide: "Issues in the Management of Depression", "Depression in the Primary Care Setting", "Antidepressants for the Long Haul"

### Audio-Conference Moderator:

- 2016 Shire – Adult ADHD Management Teleconference
- 2016 Shire – B.E.D. in Adults Teleconference
- 2007 Depression, Bipolar and Fibromyalgia
- 2006 Panic Series
- 2006 Insomnia Series
- 2005 "Treating Anxiety and Depression: Evaluating the Therapeutic Options
- 2005 "Reducing Relapse and Recurrence in Major Depressive Disorder"
- 2004 Recognition and Treatment of Attention Deficit Disorder (Ped + Adult)
- 2003 "Achieving Remission: Comparing Antidepressant Treatments"
- 2002 "Clinical Advances in the Treatment of Depression"
- 2001 "Improved Clinical Profile of A single-Isomer SSRI"

### Media Projects:

- 2016 Bradley N. Gaynes, MD, MPH; C. Brendan Montano, MD; Denise Vanacore, PhD *Primary Care Challenges in Depression – to Treat or Refer?* (2016, Oct 28) Medscape.
- Michael E. Thase, MD; C. Brendan Montano, MD; Albert Yeung, MD *Assessment and Treatment Decisions for Patients with Major Depressive Disorder CME* (2016, Mar 25) Medscape.
- Carlos M. Grilo, PhD; Leslie Citrome, MD, MPH; C. Brendan Montano, MD; Marcia Meislin, LMHC, *PCC Update on the Management of Binge Eating Disorder* (2016, Jan 27) Medscape.
- 2015 Montano CB [ADHD in Adults] (2014 Feb) *Treating ADHD in Adults is Tremendously Rewarding* Youtube.
- Rostain AL, Faraone SV, Montano CB, (2014) *Afraid of Prescribing ADHD Stimulant Medications?* ADHDinAdults.com
- Tudiso R, Montano CB (2014) *Multi-Modal Approach to treating Adult ADHD* ADHDinAdults.com
- Montano CB (2014) *Adult ADHD Success Story #4* ADHDinAdults.com
- 2010 David W. Goodman, MD; Richard H. Weisler, MD; C. Brendan Montano, MD *The Management of Adult ADHD in Primary Care* (2010, Jul 20) Medscape.
- 2009 David W. Goodman, MD; C. Brendan Montano, MD; Timothy E. Wilens, MD *Highlights of the Summit on ADHD: Targeting and Overcoming the Challenges of Diagnosing and Treating ADHD in an Adult Population* (2009, Dec 28) Medscape.
- 2008 David Goodman, MD; C. Brendan Montano, MD *Chapter 3: Optimizing Physician-Patient Communication in Adolescent ADHD* (2008, Feb 5) Medscape.
- 2006 Recognition and Management of Patients with Unresolved Symptoms of Major Depression Audio/Video
- Audio Clinical Exchange Group Practice Consult on Insomnia Live Interactive Audio and Web Conference
- 2004 "Challenging Depression - Diagnosis to Treatment" co-chair John Zajecka, MD
- 2003 C. Brendan Montano, MD *New Frontiers in the Treatment of Depression* (2003, Sep 30) Medscape.
- 2002 CD/Video: "Taking Charge: Patient Profiles" Olanzapine
- C. Brendan Montano, MD and Michael B. Montano *A New Paradigm for Treating Depression in the Primary Care Setting* (2002, Sep. 18) Medscape.
- 2000 Virtual Meeting CD Rom: Remission as a goal in the Primary Care Management of Depression and Anxiety, Education
- Video: "Antidepressants and Efficacy: Is There a Real Difference?" Norman Sussman MD, James Pradko MC, Brendan Montano MD, September Live Interactive Audio and Web Conference, CD Rom, 2 CME credits, Depression to Remission: Achieving the Goal of Complete Symptom Resolution, co-chair with Christopher Ticknor MD
- 1998 NCME Videotapes: Depression in Primary Care, with Dr. Andrew Skodol, Professor of Psychiatry at the University of Colombia #734 Depression in Primary Care: Strategies for Efficient Diagnosis #735 Depression in Primary Care: Optimizing Outcomes
- CD-ROM: The Hidden Diagnosis Series on Anxiety Disorders, case study on Social Phobia with patient interview, review of management options Treatment of Depression, Patient and Physician interviews
- 1997 Interactive Video--panel discussion with 4 field experts and 70 Southwestern Hospitals-Dallas, TX
- "Paxil at the Movies" Documentary involving the portrayal of Depression in film-Impact on disease recognition

## Publications:

- 2016 Montano CB (2016 Apr) Tactics to Improve Adherence in Depressed Primary Care Patients *J Clin Psychiatry*. 77(4):e472  
Montano CB, Rasgon NL, Herman BK (2016 Jan) Diagnosing Binge Eating Disorder in a Primary Care Setting: *Postgraduate Medicine, Volume 128(1), Pages 115-123*
- 2014 Lowry F, Montano CB (2014 Jun) Balance Test May Boost Illness Awareness in Schizophrenia. *American Society of Clinical Psychopharmacology (ASCP) 2014 Annual Meeting*. Medscape.
- 2012 Montano CB, Young J (2012 Sep) Discontinuity in the Transition from Pediatric to Adult Health Care for Patients with Attention Deficit/Hyperactivity Disorder *Postgraduate Medicine, Volume 124, Issue 5*
- 2011 Montano CB, Weisler R (2011 May) Distinguishing Symptoms of ADHD from other Psychiatric disorders in the Adult Primary Care Setting: *Postgraduate Medicine, Volume 123, Issue 3*  
Montano CB, Adler, Mattingly, Newcorn (2011 Jul) Optimizing Clinical Outcomes Across Domains of Life in Adolescents and Adults with ADHD, *Journal of Clinical Psychiatry, 72(7), 1008-1015*
- 2008 Arnold, LM Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, Wohlriech MM (2008 Oct) "The Effect of Pain on Outcomes in a Trial of Duloxetine Treatment of Major Depressive Disorder. *Annals Clinical Psychiatry: 20(4):187-93 ISSN 1547-3325*  
Adesman A, Greenberg D, Pratt, Goodman, Montano CB (2008 Feb) "Early to Late Adolescence: Issues and Challenges in the Management of ADHA". Chapter 3 "Optimizing Physician-Patient Communication in Adolescent ADHD"
- 2004 Faraone SV, Spencer TJ, Montano CB, Beiderman J (2004 Jun), "Attention Deficit/Hyperactivity Disorder in Adults: A Survey of Current Practice in Psychiatry and Primary Care"; *Archives of Internal Medicine Volume 164, number 11 pages 1157-1252*  
Sussman N, Delgado PL, Montano CB, (2004 Feb)"Treatment of Depression: Recognizing and Improving the Standard of Care" *Primary Psychiatry: Vol 11, No 2*,  
Montano CB (2004 Feb), The Diagnosis and Treatment of Adult ADHD in Primary Care: 2004 Feb. *Journal Of Clinical Psychiatry Vol 65, Supple: 3 18-21*.
- 2003 Montano CB, Ashton AK, D'Mello DA, Dantz B, Hefner J, Leon FG, Matson GA, Pradko JF, Sussman N, Winsberg B. (2003 Dec) "Response to treatment: Gaining and maintaining remission from depression." *Journal of Family Practice; supple: S9-18*  
Biederman, Adler, Culpepper, Mason, Montano, Murphy, Roth, Spencer, Weiss, Wilens (2003 Sep) "Diagnosing and Treating Attention-Deficit/Hyperactivity Disorder in Adults". *PCC Visuals CME Program# 032-999-03-060-H01*
- 2002 Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KA, Donahue RM, Jamerson BD, Metz A. (2002 Apr) "Prevalence of Sexual Dysfunction among Newer Antidepressants" *Journal of Clinical Psychiatry 63:4 357-366*  
Montano CB, Montano M "A New Paradigm for Treating Depression in the Primary Care Setting" Medscape CME article
- 1999 Montano CB (1999 Nov) "Depression and Anxiety in the Elderly: Therapeutic Challenges" *Issues in Depression: Index & Reviews, Editor in Chief, Premier Issue Volume 1, Number 1*  
Montano CB (1999) "Primary Care Issues Related to the Treatment of Depression in Elderly Patients" *Journal of Clinical Psychiatry, Treatment of Depression in Long-Term Care Patients 1999 Volume 60, Supplement 20*
- 1997 Montano CB, Katon W, Hart R (1997 May) "The Effect of Panic Disorder in the Managed Care Setting", *Managed Care Interface*
- 1994 Montano CB (1994 Dec) "Recognition and Treatment of Depression in a Primary Care Setting" *Journal of Clinical Psychiatry, Supplement Managing Depression: New Perspectives December 1994 Volume 55 No. 12*
- 1982 Sinatra, Montano CB, Hatch (1982 Jul) "Stress Management Program with Biochemical Assay" *Connecticut Medical Journal, Vol.46, No. 7*